Transformative Workflows for Protein Characterization: ECD and Multidimensional Separations

Importance of the topic

The combined advances in electron-based fragmentation and multidimensional separations have materially expanded the capability to characterize peptides, proteins, and biotherapeutics with higher confidence and depth. Techniques such as electron capture dissociation (ECD) and orthogonal separation workflows (for example, hydrophobic interaction chromatography coupled offline to capillary zone electrophoresis) resolve labile post‑translational modifications (PTMs), disulfide connectivity, charge variants and sequence isomers that frequently evade conventional collision-based MS/MS or single-dimension separations. These capabilities are essential for discovery proteomics, structural biology, and regulated biopharmaceutical development where detailed mapping of critical quality attributes (CQAs) is required for safety, efficacy and regulatory compliance.

Objectives and overview of the summarized studies

• Review the principles, analytical value and recent instrumentation advances that make ECD more accessible beyond FT‑ICR platforms.
• Demonstrate a practical multidimensional HIC → offline fractionation → CZE–UV workflow, combined with intact mass and peptide mapping using a high‑resolution Q‑TOF, to resolve and assign charge‑based microheterogeneity in monoclonal antibodies (mAbs).
• Showcase application of ECD on a benchtop Q‑TOF to comprehensively characterize synthetic GLP‑1 analogs (liraglutide, semaglutide, tirzepatide), including noncanonical residues and fatty‑acid modifications, using ExDViewer software for targeted deconvolution and fragment annotation.

Methodology and used instrumentation

• Electron capture dissociation (ECD): low‑energy electron capture by multiply charged cations to generate predominantly c and z• backbone fragments via non‑ergodic cleavage (N–Cα), preserving labile PTMs and minimizing neutral losses.
• Multidimensional separations: offline coupling of hydrophobic interaction chromatography (HIC) fractionation followed by capillary zone electrophoresis (CZE–UV) of HIC fractions to separate variants by orthogonal properties (hydrophobicity then charge/mobility).
• MS confirmation: intact mass analysis and peptide mapping (enzymatic digestion + LC/MS/MS) to assign mass shifts and map PTMs responsible for observed chromatographic/electrophoretic variants.
• GLP‑1 peptide workflow: reversed‑phase LC separation of mixed GLP‑1 analogs and targeted ECD MS/MS with complementary CID when beneficial; data processed with ExDViewer targeted deconvolution and fragment matching.

Used Instrumentation

• Agilent 6545XT AdvanceBio LC/Q‑TOF equipped with Agilent ExD cell for practical ECD on a Q‑TOF platform.
• Agilent ExDViewer and ExDControl software for ECD acquisition control, isotopically resolved MS1 deconvolution, targeted MS/MS fragment matching and visualization.
• Agilent 1290 Infinity II Bio LC system and AdvanceBio Peptide Mapping column (2.1 × 150 mm, 2.7 µm) for peptide separations.
• HIC column (AdvanceBio HIC) for hydrophobic fractionation; bare fused silica capillary and optimized electrolyte for CZE–UV separations.
• Dual Jet Stream ESI source; standard LC/MS consumables and reagents for intact and peptide analyses.

Main results and discussion

• ECD fundamentals and advantages: ECD produces c and z ions that complement CID b/y ions, enables non‑ergodic fragmentation that preserves labile PTMs (phosphorylation, glycosylation, fatty‑acid modifications) and efficiently cleaves disulfide bonds for cross‑link and folding analyses. Compared with CID, spectra show fewer neutral losses leading to cleaner modification localization.
• ECD accessibility: the ExD Cell retrofit for the 6545XT Q‑TOF demonstrates that high‑value electron‑based fragmentation can be implemented on benchtop Q‑TOFs, broadening adoption beyond FT‑ICR instruments. Variant ECD approaches (activated ion ECD, plasma ECD) further expand applicability.
• Multidimensional HIC–CZE–UV workflow (Sarin et al.): offline HIC fractionation followed by CZE–UV markedly increased resolved variant counts for two mAbs: trastuzumab (mAb A) — 29 variants; rituximab (mAb B) — 23 variants. These counts exceed single‑dimension HIC (4 variants), CZE–UV (7 variants) and prior 2DLC results (10–11 variants), demonstrating dramatic multiplication of peak capacity through orthogonality.
• Variant assignments: intact mass and peptide mapping on the 6545XT allowed assignment of C‑terminal lysine variants, deamidation/isomerization, glycoforms, oxidation and N‑terminal pyroglutamate among resolved peaks. Reproducibility metrics were strong (retention/migration time RSD <5% for trastuzumab, <3% for rituximab; peak area RSD <12%).
• GLP‑1 analog characterization: LC–ECD MS/MS of liraglutide, semaglutide and tirzepatide provided high‑quality deconvoluted MS1 masses and sequence mapping. ExDViewer achieved 100% sequence coverage for 4+ precursors and identified noncanonical residue B (2‑aminoisobutyrate) and site‑specific fatty‑acid lysine modifications. ECD generated abundant side‑chain (w) ions helping to distinguish isomeric residues (asp/iso‑asp, Leu/Ile). For low charge states (e.g., 3+ semaglutide) limited ECD cleavage was improved by adding modest collisional activation (ECD + low CE), which increased sequence coverage without broadly increasing unassigned fragment noise.
• Software benefits: ExDViewer’s targeted deconvolution and fragment scoring modeled electron fragmentation peculiarities (hydrogen transfer, side‑chain losses), enabling confident localization of custom modifications and automated visualization of fragmentation trends and data quality.

Practical benefits and applications

• Regulatory and QA/QC: improved resolution and confident PTM localization supports CQA assessment for biotherapeutics, comparability studies, and impurity/variant profiling required for regulatory filings.
• Top‑down and middle‑down proteomics: ECD enables deeper sequence coverage and intact proteoform characterization, including disulfide mapping, glycoform profiling and detection of sequence variants and isomers.
• Method complementarity: orthogonal separations (HIC → CZE) paired with MS provide a practical route to dissect heterogeneity that might be missed by single‑dimension or conventional 2DLC techniques.
• Peptide therapeutics and synthetic analogs: ECD’s preservation of labile synthetic modifications (fatty acyl attachments, linkers) makes it an ideal fragmentation method for next‑generation peptide drugs and counterfeit detection.

Future trends and opportunities

• Wider deployment of electron‑based fragmentation on compact, high‑resolution platforms will democratize top‑down capabilities across more labs, accelerating proteoform‑level analytics in industry and academia.
• Hybrid fragmentation strategies (ECD combined with low‑energy CID or supplemental activation) will become routine to address charge‑state dependent fragmentation efficiency, improving sequence coverage for low‑charge precursors.
• Improved software, AI‑driven spectral annotation and standardized fragment scoring will streamline identification/localization of complex modifications and support automated QC pipelines.
• Integration of multidimensional separations with automated fraction collection and online coupling options may increase throughput while retaining orthogonality, making such approaches more compatible with regulated workflows.
• Emerging electron‑based modalities (activated ion ECD, plasma ECD) and advances in ion optics will extend analysis to larger complexes, conjugates and difficult proteoforms.

Conclusion

The combined use of electron capture dissociation and thoughtfully designed multidimensional separations significantly elevates the analytical resolution available for protein and peptide characterization. Practical implementations—such as a field‑installable ExD cell on a benchtop Q‑TOF and an offline HIC→CZE–UV pipeline paired with high‑resolution intact mass and peptide mapping—offer powerful, reproducible solutions for resolving charge variants, mapping labile modifications and confirming proteoform identity. These workflows enhance both discovery science and regulated biopharmaceutical analytics and point to a near future where ECD and orthogonal separations are routine tools in many laboratories.

References

1. Cooper H. J.; et al. The role of electron capture dissociation in biomolecular analysis. Mass Spectrometry Reviews. 2005. DOI: 10.1002/mas.20014.
2. Sarin D.; et al. Offline Coupling of Hydrophobic Interaction Chromatography–Capillary Zone Electrophoresis for Monitoring Charge‑Based Heterogeneity of Recombinant Monoclonal Antibodies. ELECTROPHORESIS. 2024. DOI: 10.1002/elps.202400158.
3. Franklin R.; Hare M.; Walker T.; Meeuwsen J. Comprehensive Characterization of Multiple GLP‑1 Analogs Using an Agilent 6545XT AdvanceBio LC/Q‑TOF with electron capture dissociation and ExDViewer software. Agilent Technologies application note. 2024.
4. Beckman J. S.; Voinov V. G.; Hare M.; et al. Improved Protein and PTM Characterization with a Practical Electron‑Based Fragmentation on Q‑TOF Instruments. J. Am. Soc. Mass Spectrom. 2021, 32(8), 2081–2091.
5. Andersen A.; Lund A.; Knop F. K.; Vilsbøll T. Glucagon‑Like Peptide 1 in Health and Disease. Nat Rev Endocrinol. 2018, 14(7), 390–403.
6. Holst J. J. The Physiology of Glucagon‑Like Peptide 1. Physiol. Rev. 2007, 87(4), 1409–1439.
7. Wang J.; Mukherjee S.; Zubarev R. A. Isoaspartate and Neurodegeneration. Aging (Albany NY). 2022, 14(22), 8882.